FUSION PROTEIN AND MEDICAL USE THEREOF - SHANGHAI HANSOH BIOMEDICAL CO LTD

Title:

FUSION PROTEIN AND MEDICAL USE THEREOF

Document Type and Number:

WIPO Patent Application WO/2023/280144

Kind Code:

A1

Abstract:

Provided are a fusion protein consisting of an FGF21 protein and immunoglobulin Fc or fragments thereof, and a method for treating diabetes, obesity, dyslipidemia, metabolic syndrome, non-alcoholic fatty liver, non-alcoholic steatohepatitis, or other related diseases by using the FGF21-Fc fusion protein and pharmaceutical compositions thereof.

More Like This:

WO2001004148	DONOR STRAND COMPLEMENTED PILIN AND ADHESIN BROAD-BASED VACCINES
JP2001527390	INDUSTRIAL APPLICABILITY: Leaderless protein export inhibitor
JP5221510	Human prolactin antagonist-angiogenesis inhibitor fusion protein

Inventors:

MAO DONGJIE (CN)
XIE YUEJUN (CN)

Application Number:

PCT/CN2022/103825

Publication Date:

January 12, 2023

Filing Date:

July 05, 2022

Export Citation:

Click for automatic bibliography generation Help

Assignee:

SHANGHAI HANSOH BIOMEDICAL CO LTD (CN)
CHANGZHOU HANSOH PHARMACEUTICAL CO LTD (CN)
JIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD (CN)

International Classes:

C07K19/00; A61K38/19; A61P3/00; C12N15/62

Domestic Patent References:

WO2021139763A1	2021-07-15
WO2016114633A1	2016-07-21

Foreign References:

CN105792851A	2016-07-20
CN109836503A	2019-06-04
CN107995914A	2018-05-04
CN111153965A	2020-05-15
AU2014202582A1	2014-06-05
CN108290937A	2018-07-17

Other References:

HECHT, R. ET AL.: "Rationale-Based Engineering of a Potent Long-Acting FGF21 Analog for the Treatment of Type 2 Diabetes", PLOS ONE, vol. 7, no. 11, 30 November 2012 (2012-11-30), XP055192704, DOI: 10.1371/journal.pone.0049345

Attorney, Agent or Firm:

GE CHENG & CO., LTD. (CN)

Download PDF:

View/Download PDF PDF Help

Previous Patent: AI TASK CONTROL METHOD, TERMINAL, BASE STATION, AND STORAGE MEDIUM

Next Patent: INFORMATION CITING METHOD, SYSTEM AND APPARATUS, AND ELECTRONIC DEVICE